Aeglea BioTherapeutics (AGLE) Competitor Comparison
We are evaluating the key criteria listed to compare Aeglea BioTherapeutics (AGLE) against its competitors in the Biotechnology industry.
Market Capitalization
294 / 368Gross Profits
154 / 278Total Revenue
235 / 300EBITDA
198 / 337Free Cashflow
53 / 352Quick Ratio
197 / 357Earnings per Share
356 / 359Dividend yield
0 / 6Total Cash
153 / 358Performance 3 years
33 / 368Performance 5 years
65 / 368Performance 10 years
62 / 368Linearity 3 years
341 / 368Linearity 5 years
329 / 368Linearity 10 years
319 / 368Total Rank
283 / 368Dividend Rank
335 / 368Valuation Rank
128 / 368Piotroski Rank
361 / 368Muliplier Rank
255 / 368Muliplier Rank - AGLE ranking 255 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.